NEW HAVEN, Conn.— A man who fought drug trafficking in the Caribbean as a U.S. Navy officer before beginning a finance career in Connecticut was sentenced Tuesday to two years and nine months in prison for misleading investors about accounts in the Cayman Islands. David Bryson, who was sentenced in New Haven federal court, is among three former executives of...» Read More
As the global population ages, some see investment opportunities in somewhat ghoulish bets the rates of cancer and other illnesses will rise.
CNBC's Andrea Day looks into the FBI's investigation of the Los Zetas drug cartel, which used horse racing to launder money.
Orexigen Therapeutics said the FDA delayed a decision on its obesity drug by three months, sending the company's shares down about 19 percent.
But Merck chief Kenneth Frazier also said the government needs to modify its high corporate tax code to level the playing field for American companies.
Chicago filed a lawsuit against five pharmaceutical companies, accusing them of concealing the risks associated with certain painkillers.
Patients can try new once-a-day tablets that dissolve quickly under the tongue and raise tolerance to grass or ragweed pollen, much like the shots.
The announcement that GSK is planning to spend $350 million plus to get a slice of a U.K. biotech's cancer drugs has raised eyebrows.
This year's biggest cancer conference begins tomorrow. CNBC's Meg Tirrell reports why immunotherapy drugs will be a key theme with drug makers at ASCO.
GSK has invited private equity firms to consider making offers for a range of its older drugs, three people with direct knowledge of the matter said.
CNBC's Meg Tirrell reports shares of PTC Therapeutics are surging on a recommendation of the drug "Ataluren" designed to treat Duchenne muscular dystrophy which could be a billion dollar drug.
Pfizer's pursuit of AstraZeneca raises a huge public policy red flag, writes Andrew Ross Sorkin in the New York Times.
Colombian Finance Minister Mauricio Cárdenas Santamaria says resolving the country's drugs issue will help the country post stronger growth.
CNBC's Meg Tirrell speaks with George Scangos, Biogen Idec CEO, about the drug maker's fight against MS and Alzheimer's. Scangos also comments on Valeant's bid for Alllergan.
Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.
The hemp industry could become one of the U.S.'s biggest now its industrial use had been legalized, says Doug Fine, author of "Hemp Bound".
Luis Videgaray, finance minister of Mexico, says the U.S. must "share responsibility" for tackling drug cartels.
Ian Read, Pfizer CEO, discusses the pricing and affordability of drugs in the U.S. Read also weighs in on insurance coverage under the Affordable Care Act.
Mallinckrodt is buying drug maker Questcor for $5.6 billion. Barbara Ryan, FTI Consulting managing director, discusses consolidation in pharmaceuticals and shares what stocks she likes in the space.
Why do some drugs, like Gilead's Sovaldi, cost more in the U.S. than in other countries. Shelia Dharmarajian reports for "Nightly Business Report."
Almost half of Americans ages 40 to 75 qualify to consider cholesterol-lowering statin drugs under new heart disease prevention guidelines.